The Melanoma Content Hub Channel

Dr. Hamid on Promising Triplet Combinations Under Exploration in Melanoma

In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that suggests progression-free survival (PFS) is increased with the use of these targeted therapies.

Learn more by clicking here.

More in Melanoma Content Hub

►

Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies

Melanoma Content Hub

Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination of nivolumab...

► 1:45

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

Melanoma Content Hub

Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses...

►

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

Melanoma Content Hub

Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition. FMT patients...

►

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Melanoma Content Hub

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the assessment of...